---
title: "Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603590.SH.md"
symbol: "603590.SH"
name: "Beijing Konruns Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-19T22:49:39.588Z"
locales:
  - [en](https://longbridge.com/en/quote/603590.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603590.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603590.SH.md)
---

# Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SH)

## Company Overview

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.konruns.cn](https://www.konruns.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: B (0.38)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 44 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.52% |  |
| Net Profit YoY | 274.35% |  |
| P/B Ratio | 1.68 |  |
| Dividend Ratio | 1.77% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5399605029.66 |  |
| Revenue | 917115084.44 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.29% | C |
| Profit Margin | 18.38% | A |
| Gross Margin | 89.81% | A |
| Revenue YoY | 9.52% | B |
| Net Profit YoY | 274.35% | A |
| Total Assets YoY | 4.94% | C |
| Net Assets YoY | 1.98% | C |
| Cash Flow Margin | 99.47% | C |
| OCF YoY | 9.52% | B |
| Turnover | 0.23 | D |
| Gearing Ratio | 13.97% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Beijing Konruns Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.52%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "274.35%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.68",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.77%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5399605029.66",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "917115084.44",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.29%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "18.38%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "89.81%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "9.52%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "274.35%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.94%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.98%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "99.47%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "9.52%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.23",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.97%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 32.81 | 77/215 | 158.59 | 119.12 | 107.51 |
| PB | 1.72 | 62/215 | 2.68 | 2.11 | 1.78 |
| PS (TTM) | 6.03 | 143/215 | 9.63 | 7.72 | 6.42 |
| Dividend Yield | 1.73% | 78/215 | 1.62% | 1.40% | 1.11% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-07-09T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 34.81 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603590.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603590.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603590.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603590.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**